Literature DB >> 34393221

[Clinicopathological features and prognosis of fumarate hydratase deficient renal cell carcinoma].

Y F Yu1, S M He1, Y C Wu1, S W Xiong1, Q Shen1, Y Y Li1, F Yang1, Q He1, X S Li1.   

Abstract

OBJECTIVE: To investigate the clinicopathological features and prognosis of fumarate hydratase deficient renal cell carcinoma (FH-RCC).
METHODS: Immunohistochemical (IHC) staining was used to detect the expression of fumarate hydratase (FH) in tumor tissues of 109 different types of renal cell carcinoma (RCC) patients aged 60 years and younger from the Department of Urology of Peking University First Hospital from January 2013 to December 2019. The clinicopathological data and prognosis of FH-RCC were collected and analyzed.
RESULTS: There were eleven patients with FH-negative expression. Seven were males and four females. The age of onset ranged 16-53 years (mean age: 36.7 years), and four female patients all had a history of uterine leiomyoma. Only one first-degree relative of one patient had renal cancer, and none of the patients had a history or family history of cutaneous leiomyomas. The diameter of the tumor was 2.1-12.0 cm (mean: 8.83 cm). Renal sinus or perirenal fat invasion was seen in nine cases, tumor thrombus in renal vein or inferior vena cava in six cases, lymph node metastasis in seven cases, adrenal gland invasion in four cases and splenic capsule invasion in one case. The cases were initially diagnosed as type Ⅱ papillary RCC (7/49, 14.3%), collecting duct carcinoma (2/9, 22.2%) and unclassified RCC (2/51, 3.9%). Tumor histopathology mostly showed a mixture of different structures, such as papillary, tubular cystic, solid, and so on. The most common histological structures were papillary (9/11, 81.8%) and tubular (8/11, 72.7%). Three cases had sarcomatoid areas. At least focal eosinophilic nucleolus (WHO/grades Ⅲ-Ⅳ) and perinuclear halo could be seen in all cases. Immunohistochemical (IHC) stains of most tumors were negative for CA9, CD10 and CK7. The results of fluorescence in situ hybridization (FISH) showed that there was no translocation or amplification of TFE3 gene in two cases with TFE3 IHC expression. All the patients were followed up for 11-82 months. Mean survival was 24 months. Five cases died of distant metastasis 9-31 months after operation (mean: 19 months), and five of the six patients alive had became metastatic.
CONCLUSION: Morphologically, FH-RCC overlaps with many types cell RCC. A mixture of papillary and tubular cystic arrangement is the most common growth pattern of FH-RCC. At least focally large and obvious eosinophilic nucleoli are an important histological feature of this tumor. The negative expression of FH can help to confirm the diagnosis. Young female RCC patients with uterine leiomyomas should be suspected of FH-RCC. Some FH-RCC cases lack clinical evidence. The suspicion raised by pathologists based on histological characteristics is often the key step to further genetic testing and the final diagnosis of the tumor.

Entities:  

Keywords:  Fumarate hydratase; Immunohistochemistry; Prognosis; Renal cell carcinoma

Mesh:

Substances:

Year:  2021        PMID: 34393221      PMCID: PMC8365061     

Source DB:  PubMed          Journal:  Beijing Da Xue Xue Bao Yi Xue Ban        ISSN: 1671-167X


  32 in total

1.  Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma.

Authors:  Chisato Ohe; Steven C Smith; Deepika Sirohi; Mukul Divatia; Mariza de Peralta-Venturina; Gladell P Paner; Abbas Agaimy; Mitual B Amin; Pedram Argani; Ying-Bei Chen; Liang Cheng; Maurizio Colecchia; Eva Compérat; Isabela Werneck da Cunha; Jonathan I Epstein; Anthony J Gill; Ondřej Hes; Michelle S Hirsch; Wolfram Jochum; Lakshmi P Kunju; Fiona Maclean; Cristina Magi-Galluzzi; Jesse K McKenney; Rohit Mehra; Gabriella Nesi; Adeboye O Osunkoya; Maria M Picken; Priya Rao; Victor E Reuter; Paulo Guilherme de Oliveira Salles; Luciana Schultz; Satish K Tickoo; Scott A Tomlins; Kiril Trpkov; Mahul B Amin
Journal:  Am J Surg Pathol       Date:  2018-03       Impact factor: 6.394

2.  Fumarate Hydratase-deficient Renal Cell Carcinoma Is Strongly Correlated With Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome.

Authors:  Kiril Trpkov; Ondrej Hes; Abbas Agaimy; Michael Bonert; Petr Martinek; Cristina Magi-Galluzzi; Glen Kristiansen; Christine Lüders; Gabriella Nesi; Eva Compérat; Mathilde Sibony; Daniel M Berney; Rohit Mehra; Fadi Brimo; Arndt Hartmann; Arjumand Husain; Norma Frizzell; Kirsten Hills; Fiona Maclean; Bhuvana Srinivasan; Anthony J Gill
Journal:  Am J Surg Pathol       Date:  2016-07       Impact factor: 6.394

Review 3.  Hereditary leiomyomatosis and renal cell cancer syndrome: An update and review.

Authors:  Viral M Patel; Marc Z Handler; Robert A Schwartz; W Clark Lambert
Journal:  J Am Acad Dermatol       Date:  2017-03-14       Impact factor: 11.527

4.  Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America.

Authors:  Jorge R Toro; Michael L Nickerson; Ming-Hui Wei; Michelle B Warren; Gladys M Glenn; Maria L Turner; Laveta Stewart; Paul Duray; Ousman Tourre; Nirmala Sharma; Peter Choyke; Pamela Stratton; Maria Merino; McClellan M Walther; W Marston Linehan; Laura S Schmidt; Berton Zbar
Journal:  Am J Hum Genet       Date:  2003-05-22       Impact factor: 11.025

5.  Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency.

Authors:  N A Alam; A J Rowan; N C Wortham; P J Pollard; M Mitchell; J P Tyrer; E Barclay; E Calonje; S Manek; S J Adams; P W Bowers; N P Burrows; R Charles-Holmes; L J Cook; B M Daly; G P Ford; L C Fuller; S E Hadfield-Jones; N Hardwick; A S Highet; M Keefe; S P MacDonald-Hull; E D A Potts; M Crone; S Wilkinson; F Camacho-Martinez; S Jablonska; R Ratnavel; A MacDonald; R J Mann; K Grice; G Guillet; M S Lewis-Jones; H McGrath; D C Seukeran; P J Morrison; S Fleming; S Rahman; D Kelsell; I Leigh; S Olpin; I P M Tomlinson
Journal:  Hum Mol Genet       Date:  2003-06-01       Impact factor: 6.150

6.  Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Al B Benson; Alan P Venook; Mahmoud M Al-Hawary; Lynette Cederquist; Yi-Jen Chen; Kristen K Ciombor; Stacey Cohen; Harry S Cooper; Dustin Deming; Paul F Engstrom; Jean L Grem; Axel Grothey; Howard S Hochster; Sarah Hoffe; Steven Hunt; Ahmed Kamel; Natalie Kirilcuk; Smitha Krishnamurthi; Wells A Messersmith; Jeffrey Meyerhardt; Mary F Mulcahy; James D Murphy; Steven Nurkin; Leonard Saltz; Sunil Sharma; David Shibata; John M Skibber; Constantinos T Sofocleous; Elena M Stoffel; Eden Stotsky-Himelfarb; Christopher G Willett; Evan Wuthrick; Kristina M Gregory; Lisa Gurski; Deborah A Freedman-Cass
Journal:  J Natl Compr Canc Netw       Date:  2018-07       Impact factor: 11.908

7.  Pattern multiplicity and fumarate hydratase (FH)/S-(2-succino)-cysteine (2SC) staining but not eosinophilic nucleoli with perinucleolar halos differentiate hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinomas from kidney tumors without FH gene alteration.

Authors:  Marie Muller; Marine Guillaud-Bataille; Julia Salleron; Catherine Genestie; Sophie Deveaux; Abdelhamid Slama; Brigitte Bressac de Paillerets; Stéphane Richard; Patrick R Benusiglio; Sophie Ferlicot
Journal:  Mod Pathol       Date:  2018-02-06       Impact factor: 7.842

8.  Hereditary leiomyomatosis and renal cell cancer: update on clinical and molecular characteristics.

Authors:  Heli J Lehtonen
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.446

9.  Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients.

Authors:  Yeonjoo Choi; Bhumsuk Keam; Miso Kim; Shinkyo Yoon; Dalyong Kim; Jong Gwon Choi; Ja Young Seo; Inkeun Park; Jae Lyun Lee
Journal:  Cancer Res Treat       Date:  2019-03-25       Impact factor: 4.679

Review 10.  Renal cell carcinoma in young FH mutation carriers: case series and review of the literature.

Authors:  J A Hol; M C J Jongmans; A S Littooij; R R de Krijger; R P Kuiper; J J T van Harssel; A Mensenkamp; M Simons; G A M Tytgat; M M van den Heuvel-Eibrink; M van Grotel
Journal:  Fam Cancer       Date:  2020-01       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.